The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Immune toxicity and flow cytometry of circulating blood cells in cancer patients receiving immune therapy.
 
Saad A. Khan
Honoraria - ARIAD; EMD Serono; Genentech/Roche; Genzyme
Consulting or Advisory Role - ARIAD; Bayer/Onyx; Bayer/Onyx; EMD Serono; Foundation Medicine; Genentech/Roche; Guardant Health; Oak Ridge Associated Universities; Takeda
Speakers' Bureau - Genzyme; Takeda
Research Funding - Abbvie (Inst); Bayer/Onyx (Inst); Bayer/Onyx (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Formation Biologics (Inst); Genentech (Inst); Gilead Sciences (Inst); Guardant Health (Inst); Loxo (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Threshold Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Genentech; Novartis
 
Noah Sorrelle
No Relationships to Disclose
 
Rolf A. Brekken
Leadership - Tuevol Therapeutics
Stock and Other Ownership Interests - Regeneron
Consulting or Advisory Role - BerGenBio; Peregrine Pharmaceuticals; Synergys Biotherapeutics
Research Funding - BerGenBio; CellMid; Lilly; Mirati Therapeutics; Oncologie; Peregrine Pharmaceuticals; Tolero Pharmaceuticals
Patents, Royalties, Other Intellectual Property - I am on multiple patents relevant to vascular targeting, VEGF inhibition and DDR1 inhibitors that have been licensed by companies from the University of Texas
Travel, Accommodations, Expenses - BerGenBio; Peregrine Pharmaceuticals
 
Rong Lu
No Relationships to Disclose
 
Mitchell S. von Itzstein
No Relationships to Disclose
 
Donglu Xie
No Relationships to Disclose
 
David Hsieh
No Relationships to Disclose
 
Yvonne Gloria-McCutchen
No Relationships to Disclose
 
Jessica Saltarski
No Relationships to Disclose
 
Mary Watters
No Relationships to Disclose
 
Benjamin Aaron Bleiberg
No Relationships to Disclose
 
Vinita Popat
No Relationships to Disclose
 
Murtaza Ahmed
No Relationships to Disclose
 
Yuqing Zhang
No Relationships to Disclose
 
Farjana Fattah
No Relationships to Disclose
 
Shaheen Khan
Patents, Royalties, Other Intellectual Property - Shaheen Khan reports a U.S. patent pending (62/654,025)
 
Jason Park
Stock and Other Ownership Interests - Targeted Diagnostics & Therapeutics
Consulting or Advisory Role - Miraca Holdings
Patents, Royalties, Other Intellectual Property - Thomas Jeff Univ, 12 patents; GUCY2C, TAK-164 technology. Univ of Pennsylvania, 2 patents on nanotechnology. UT Southwestern, 2 patent application on immunotherapy biomarkers. (Inst)
 
David E. Gerber
Stock and Other Ownership Interests - Gilead Sciences
Consulting or Advisory Role - Samsung Bioepis
Research Funding - AstraZeneca (Inst); BerGenBio (Inst); Karyopharm Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Patent pending: “Prediction and Treatment of Immunotherapeutic Toxicity” (provisional, application number 62/461,455) (Inst); Royalties from Decision Support in Medicine from the Clinical Decision Support--Oncology on-line program.; Royalties from Oxford University Press from two books.